Mumbai, Jul 9 : Pharma major Lupin Limited (Lupin) announced the launch of Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base).
Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier, a company's release said.
Lupin’s Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), is a generic version of Novartis Pharmaceuticals Corporation’s (Novartis) Gleevec Tablets, 100 mg and 400 mg.
It is indicated for the treatment of Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (UNI)